SuperworthClimb Bio market cap CLYM
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $585.3M
- Highest close in our data
- $992.5M
- Aug 2026
Climb Bio is worth $585.3M at the close on Oct 23, 2026, at $10.19 a share.
That is up 334% over the last year.
Its highest close in our data was $992.5M in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $585.3M | $255.7M | $992.5M | +74% |
| 2025 | $336.1M | $78.9M | $336.1M | +138% |
| 2024 | $141.2M | $131.1M | $567.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Climb Bio's size, closest first, today.
| Company | Market cap |
|---|---|
| CLYMClimb Bio | $585.3M |
| ZVRAZevra Therapeutics | $582.6M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| PBYIPuma Biotechnology | $568.9M |
| CRMDCorMedix | $611.9M |
| ARVNArvinas | $477.3M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| PCRXPacira BioSciences | $1.5B |
| Peer median | $679.7M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Climb Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.